Analytical Data
-
Gene name
ACADS
- Application
-
Alternative Names
ACADS；Short-chain specific acyl-CoA dehydrogenase. mitochondrial
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P16219
-
Expression Region
全长
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MLHTIYQSVE LPETHQMLLQ TCRDFAEKEL FPIAAQVDKE HLFPAAQVKK MGGLGLLAMD VPEELGGAGL DYLAYAIAME EISRGCASTG VIMSVNNSLY LGPILKFGSK EQKQAWVTPF TSGDKIGCFA LSEPGNGSDA GAASTTARAE GDSWVLNGTK AWITNAWEAS AAVVFASTDR ALQNKSISAF LVPMPTPGLT LGKKEDKLGI RGSSTANLIF EDCRIPKDSI LGEPGMGFKI AMQTLDMGRI GIASQALGIA QTALDCAVNY AENRMAFGAP LTKLQVIQFK LADMALALES ARLLTWRAAM LKDNKKPFIK EAAMAKLAAS EAATAISHQA IQILGGMGYV TEMPAERHYR DARITEIYEG TSEIQRLVIA GHLLRSYRS
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ACADS, or acyl-CoA dehydrogenase, is an essential enzyme involved in the metabolism of fatty acids and amino acids, playing a critical role in the mitochondrial fatty acid oxidation pathway. Deficiencies or genetic mutations in the ACADS gene can lead to medium-chain acyl-CoA dehydrogenase deficiency (MCADD), a disorder that disrupts the body's ability to convert certain fats into energy, particularly during periods of fasting or illness. This condition can result in severe metabolic crises, including hypoglycemia and acidosis, leading to neurological damage or even death if not promptly managed. The research on recombinant ACADS proteins aims to develop effective therapeutic options for affected individuals. By producing and studying recombinant forms of ACADS, scientists can better understand the enzyme's structure-function relationships, the impact of specific mutations, and the biochemical pathways involved in fatty acid metabolism. Furthermore, insights gained from these studies can facilitate the design of gene therapy approaches or enzyme replacement therapies that may restore normal metabolic function in patients with ACADS deficiencies. Such advancements are crucial for improving diagnosis, treatment, and overall outcomes for individuals affected by related metabolic disorders.
